Mechanisms of Resistance to PD-1 and PD-L1 Blockade

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Cancer immunotherapy with PD-1/PD-L1 checkpoint inhibitors has transformed malignancy treatment.
• Durable responses are observed, surpassing traditional cytotoxic agents.
• However, primary and acquired resistance limit efficacy in many patients.

Purpose of the Study:

• To review the mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade.
• To highlight the development of novel strategies to overcome resistance.
• To improve patient outcomes in cancer immunotherapy.

Main Methods:

• Literature review of studies on PD-1/PD-L1 pathway and resistance mechanisms.
• Analysis of clinical data on immunotherapy response and resistance.
• Synthesis of current research on novel therapeutic strategies.

Main Results:

• PD-1/PD-L1 blockade resistance is multifactorial and overlapping.
• Mechanisms include tumor-intrinsic and extrinsic factors.
• Emerging strategies aim to restore T-cell function and overcome resistance.

Conclusions:

• Resistance to PD-1/PD-L1 inhibitors remains a significant challenge in cancer treatment.
• Further characterization of resistance mechanisms is crucial.
• Development of novel therapeutic approaches holds promise for enhancing immunotherapy efficacy.